ATE240402T1 - Phosphoglycan-mimetika von hormonen und wachstumfaktoren aus mycobacterium vaccae - Google Patents

Phosphoglycan-mimetika von hormonen und wachstumfaktoren aus mycobacterium vaccae

Info

Publication number: ATE240402T1
Authority: AT; Austria
Prior art keywords: pct; messenger; mimetic; sec; phosphoglycan
Prior art date: 1995-03-21

Application number

AT96907595T

Other languages

English (en)

Inventor

T W Rademacher

H N Caro

G A W Rook

Original Assignee

Innopeg Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-21

Filing date

1996-03-20

Publication date

2003-05-15

1996-03-20 Application filed by Innopeg Ltd filed Critical Innopeg Ltd

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE240402T1 publication Critical patent/ATE240402T1/de

Links

241000187644 Mycobacterium vaccae Species 0.000 title abstract 2
239000003102 growth factor Substances 0.000 title abstract 2
229940088597 hormone Drugs 0.000 title abstract 2
239000005556 hormone Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
SUHQNCLNRUAGOO-KQCZLNONSA-N (4s,5r,6r,7s,8r)-4,6,7,8,9-pentahydroxy-5-[(2-hydroxyacetyl)amino]-2-oxononanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](NC(=O)CO)[C@@H](O)CC(=O)C(O)=O SUHQNCLNRUAGOO-KQCZLNONSA-N 0.000 abstract 1
206010001324 Adrenal atrophy Diseases 0.000 abstract 1
208000007848 Alcoholism Diseases 0.000 abstract 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010067125 Liver injury Diseases 0.000 abstract 1
241000186359 Mycobacterium Species 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
206010001584 alcohol abuse Diseases 0.000 abstract 1
208000025746 alcohol use disease Diseases 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
229960000258 corticotropin Drugs 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
231100000234 hepatic damage Toxicity 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000008818 liver damage Effects 0.000 abstract 1
244000005700 microbiome Species 0.000 abstract 1
230000003278 mimic effect Effects 0.000 abstract 1
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
230000000451 tissue damage Effects 0.000 abstract 1
231100000827 tissue damage Toxicity 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/46—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/863—Mycobacterium

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)

AT96907595T 1995-03-21 1996-03-20 Phosphoglycan-mimetika von hormonen und wachstumfaktoren aus mycobacterium vaccae ATE240402T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9505658.6A GB9505658D0 (en)	1995-03-21	1995-03-21	Hormone and growth factor mimetics
PCT/GB1996/000669 WO1996029425A1 (en)	1995-03-21	1996-03-20	Hormone and growth factor phosphoglycan mimetics from mycobacterium vaccae

Publications (1)

Publication Number	Publication Date
ATE240402T1 true ATE240402T1 (de)	2003-05-15

Family

ID=10771553

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96907595T ATE240402T1 (de)	1995-03-21	1996-03-20	Phosphoglycan-mimetika von hormonen und wachstumfaktoren aus mycobacterium vaccae

Country Status (10)

Country	Link
US (1)	US6106822A (de)
EP (1)	EP0815255B1 (de)
JP (1)	JPH11503307A (de)
AT (1)	ATE240402T1 (de)
AU (1)	AU713221B2 (de)
DE (1)	DE69628155T2 (de)
DK (1)	DK0815255T3 (de)
ES (1)	ES2199285T3 (de)
GB (1)	GB9505658D0 (de)
WO (1)	WO1996029425A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9618930D0 (en) *	1996-09-11	1996-10-23	Univ London	Metal containing carbohydrates from human tissue which regulate lipogenic activity
GB9618934D0 (en) *	1996-09-11	1996-10-23	Univ London	Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
GB9618929D0 (en) *	1996-09-11	1996-10-23	Univ London	Metal containing carbohydrates from human tissue which regulate glycogen metabolism
GB9805771D0 (en) *	1998-03-18	1998-05-13	Hoeft Rademacher Limited	Materials and methods relating to screening for inositolphosphoglycan mimetics
WO1999047565A1 (en) *	1998-03-18	1999-09-23	Rademacher Group Limited	Anti-inositolphosphoglycan monoclonal antibodies
GB9806645D0 (en) *	1998-03-27	1998-05-27	Univ London	Materials and methods relating to the treatment of conditions involving mast cells,basophils and eosinophils
GB0010496D0 (en) *	2000-04-28	2000-06-14	Stanford Rook Ltd	Treatment of conditions of the central nervous system
US8779053B2 (en)	2003-08-25	2014-07-15	Dow Global Technologies Llc	Coating compositions
US7803865B2 (en)	2003-08-25	2010-09-28	Dow Global Technologies Inc.	Aqueous dispersion, its production method, and its use
US8349929B2 (en) *	2003-08-25	2013-01-08	Dow Global Technologies Llc	Coating composition and articles made therefrom
US7763676B2 (en)	2003-08-25	2010-07-27	Dow Global Technologies Inc.	Aqueous polymer dispersions and products from those dispersions
US8357749B2 (en)	2003-08-25	2013-01-22	Dow Global Technologies Llc	Coating composition and articles made therefrom
US9169406B2 (en)	2003-08-25	2015-10-27	Dow Global Technologies Llc	Coating compositions
US8722787B2 (en)	2003-08-25	2014-05-13	Dow Global Technologies Llc	Coating composition and articles made therefrom
US8946329B2 (en)	2003-08-25	2015-02-03	Dow Global Technologies Llc	Coating compositions
GB0716778D0 (en) *	2007-08-29	2007-10-10	Bioeos Ltd	Use
US9422444B2 (en)	2012-12-28	2016-08-23	Dow Global Technologies Llc	Coating compositions
JP6258968B2 (ja)	2012-12-28	2018-01-10	ダウグローバルテクノロジーズエルエルシー	コーティング組成物およびそれから作製される物品

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8919321D0 (en) *	1989-08-25	1989-10-11	Univ London	Treatment of chronic inflammatory conditions
GB9203814D0 (en) *	1992-02-21	1992-04-08	Univ London	Treatment of long term auto-immune conditions

1995
- 1995-03-21 GB GBGB9505658.6A patent/GB9505658D0/en active Pending
1996
- 1996-03-20 ES ES96907595T patent/ES2199285T3/es not_active Expired - Lifetime
- 1996-03-20 DE DE69628155T patent/DE69628155T2/de not_active Expired - Lifetime
- 1996-03-20 JP JP8528199A patent/JPH11503307A/ja not_active Ceased
- 1996-03-20 WO PCT/GB1996/000669 patent/WO1996029425A1/en not_active Ceased
- 1996-03-20 AT AT96907595T patent/ATE240402T1/de not_active IP Right Cessation
- 1996-03-20 DK DK96907595T patent/DK0815255T3/da active
- 1996-03-20 AU AU51164/96A patent/AU713221B2/en not_active Ceased
- 1996-03-20 EP EP96907595A patent/EP0815255B1/de not_active Expired - Lifetime
- 1996-03-20 US US08/913,604 patent/US6106822A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK0815255T3 (da)	2003-09-15
ES2199285T3 (es)	2004-02-16
GB9505658D0 (en)	1995-05-10
US6106822A (en)	2000-08-22
DE69628155D1 (de)	2003-06-18
EP0815255A1 (de)	1998-01-07
EP0815255B1 (de)	2003-05-14
JPH11503307A (ja)	1999-03-26
DE69628155T2 (de)	2003-12-18
WO1996029425A1 (en)	1996-09-26
AU713221B2 (en)	1999-11-25
AU5116496A (en)	1996-10-08

Legal Events

Date

Code

Title

Description

2004-01-15

UEP

Publication of translation of european patent specification

Ref document number: 0815255

Country of ref document: EP

2005-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69628155D1 (de)	2003-06-18	Phosphoglycan-mimetika von hormonen und wachstumfaktoren aus mycobacterium vaccae
Van den Berghe et al.	1997	Thyrotrophin and prolactin release in prolonged critical illness: Dynamics of spontaneous secretion and effects of growth hormone‐secretagogues
GR3021713T3 (en)	1997-02-28	The combination of growth hormone and insulin-like growth factor-i enhances growth
SE9102798D0 (sv)	1991-09-26	Nytt konjugat, dess framstaellning och anvaendning samt substrat preparerat med konjugatet
ES2168302T3 (es)	2002-06-16	Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
NO940436D0 (no)	1994-02-09	Forlenget avgivelse av peptider
CA2013379A1 (en)	1990-12-01	Automatically-effected move of a subscriber between electronic message service systems in a network
ATE155045T1 (de)	1997-07-15	Vorrichtung zur verabreichung von heilmitteln
EP0671922A4 (de)	1996-08-21	Verflüssigte darmsubmukosa und ihre verwendung als injizierbares gewebetransplantat.
ES2043890T3 (es)	1994-01-01	Nuevo uso medico.
NO2012003I1 (no)	2012-02-13	4-aminopyridin eller et derivat derav
DE69027217D1 (de)	1996-07-04	Behandlung von insulinresistentem diabetes
NO994248L (no)	1999-10-20	Startsett med nikotinsyrepreparater
SE9201573D0 (sv)	1992-05-19	Use of igf-1
TW248566B (de)	1995-06-01
EP0766966A3 (de)	2001-02-28	Methode zur Behandlung der Insulinresistenz
ATE64526T1 (de)	1991-07-15	Zubereitung von pregnanolol in einer stabilen oel- in-wasser-emulsion.
BG104135A (en)	2000-10-31	Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion
DE59308848D1 (de)	1998-09-10	Anwendung von urodilatin bei lungen- und bronchialerkrankungen
KR950703353A (ko)	1995-09-20	인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
DK0607278T3 (da)	2002-06-17	Fremgangsmåde til forstærkning af tarmabsorption
DE68918944D1 (de)	1994-11-24	Künstliche rezeptor-analoge.
SG49785A1 (en)	1998-06-15	Use of 17 alpha dihydroequilenin for lowering cholesterol
DE69221725D1 (de)	1997-09-25	Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
Swallow	1978	Antiviral agents